Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oxford BioMedica ( (GB:OXB) ) has provided an update.
Oxford Biomedica announced that its Chief Innovation Officer, Kyriacos Mitrophanous, exercised 26,210 LTIP options and sold the same number of shares at an average price of £5.758376 per share. This transaction, conducted on the London Stock Exchange, reflects ongoing managerial activities and may have implications for stakeholders monitoring insider transactions.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £970.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Spark’s Take on GB:OXB Stock
According to Spark, TipRanks’ AI Analyst, GB:OXB is a Neutral.
Oxford BioMedica’s overall score reflects strong earnings call insights and positive corporate events, indicating strategic growth and leadership confidence. However, financial performance challenges and valuation concerns moderate the score.
To see Spark’s full report on GB:OXB stock, click here.
More about Oxford BioMedica
Oxford Biomedica (LSE: OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. With 30 years of experience, the company is a pioneer in viral vector development and collaborates with leading pharmaceutical and biotechnology companies. It offers a range of technologies for viral vector manufacturing and has facilities in the UK, France, and the US.
YTD Price Performance: 40.0%
Average Trading Volume: 260,365
Technical Sentiment Signal: Buy
Current Market Cap: £706.8M
See more data about OXB stock on TipRanks’ Stock Analysis page.